Close Menu

NEW YORK – MDxHealth reported on Wednesday that its third quarter revenues fell 6 percent year over year, primarily due to the impact from the COVID-19 pandemic.

For the three months ended Sept. 30, the Belgian molecular diagnostics firm's revenue for the fell to $4.5 million from $4.7 million in Q3 2019.

The firm saw a 17 percent decline in ConfirmMDx prostate cancer test volume to 3,579 tests from 4,305 in Q3 2019. It also saw a 24 percent decline in SelectMDx prostate cancer test volume to 3,237 from 4,273 compared to the prior year period.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.